Covidien has reported six-month results from a study assessing the effectiveness of plaque excision as a frontline therapy for the treatment of peripheral arterial disease.
The study is evaluating the one-year patency rates in patients with claudication and limb salvage in patients with critical limb ischaemia after treatment with Covidien’s catheter-based SilverHawk/TurboHawk plaque excision systems.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Of the 800 patients enrolled, 624 patients had a six-month follow-up. Of these, primary patency in claudicants was 94.1% and freedom from major unplanned amputation of the target limb at six months in critical limb ischaemia patients was 97.3%.
The final results at 12 months will be available in 2012.
